Mifepristone NDC 84670-014

NDC codes

FDA NDC Directory

Product NDC (as listed)84670-014Labeler and product segments. Claims need a package NDC.

Product NDC at billing width84670-0014Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
84670-014-01	84670001401	1 TABLET in 1 BLISTER PACK (84670-014-01)Marketed from Jul 29, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mifepristone
Generic name (nonproprietary): mifepristone
Active ingredients: Mifepristone — 200 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Evita Solutions LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216616
Marketing start: Jul 29, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Progestational Hormone Receptor Antagonists (Mechanism)
Identifiers: Product ID 84670-014_5ae0d573-8257-bb22-e063-6394a90a8faaSPL ID 5ae0d573-8257-bb22-e063-6394a90a8faaSPL set ID 839d7a7d-de19-42bd-8810-132b3c2a5dafRxCUI 311704UNII 320T6RNW1FUPC 0384670014018
Pharmacologic class: Progestin Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N484670001401 followed by a unit qualifier and the quantity

Package 84670-0014-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 12, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Mifepristone Tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. Mifepristone Tablets, 200 mg is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)